menu
    • menu
    [{"orgOrder":0,"company":"Bosnalijek","sponsor":"Monitor CRO","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BOSNIA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"Lysozyme","moa":"Bacterial cell wall","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Bosnalijek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Bosnalijek \/ Monitor CRO","highestDevelopmentStatusID":"10","companyTruncated":"Bosnalijek \/ Monitor CRO"},{"orgOrder":0,"company":"Bosnalijek","sponsor":"Monitor CRO","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BOSNIA","productType":"Undisclosed","year":"2017","type":"Inapplicable","leadProduct":"EK-12","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase III","graph3":"Bosnalijek","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Bosnalijek \/ Monitor CRO","highestDevelopmentStatusID":"10","companyTruncated":"Bosnalijek \/ Monitor CRO"},{"orgOrder":0,"company":"Bosnalijek","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"BOSNIA","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Metenkephalin","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Bosnalijek","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Bosnalijek \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Bosnalijek \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Bosnalijek

    Menu

    Bosnalijek

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Bosnalijek

                            Bosnia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Bosnalijek

                            Bosnia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metenkephalin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patient...

                            Details : Metenkephalin is a Peptide drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            May 05, 2020

                            Lead Product(s) : Metenkephalin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Bosnalijek

                            Bosnia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Bosnalijek

                            Bosnia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EK-12

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Monitor CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase IIIb, Multicenter, International Study to Evaluate the Efficacy, Safety and Tolerability of EK-12 in P...

                            Details : EK-12 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Multiple Sclerosis, Relapsing-Remitting.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 14, 2017

                            Lead Product(s) : EK-12

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Monitor CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Bosnalijek

                            Bosnia arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Bosnalijek

                            Bosnia arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lysozyme

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Monitor CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of the Lysobact Complete Spray®, Tantum Verde® and Pharyngal® Oromucosal Spray in...

                            Details : Lysozyme is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pharyngitis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            September 13, 2017

                            Lead Product(s) : Lysozyme

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Monitor CRO

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth